EAST - [default.wsp:1]

File View Edit Tools Window Help

Drafts
Pending

Search | List | Browse | Queue | Clear

BRS f... | IS&R ... | Image | Text | HTML

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Err
1	BRS	L1	423	cryptat$	USPAT	2003/03/14 09:59			0
2	BRS	L2	3280	424/1.11-9.4.ccls.	USPAT	2003/03/14 09:54			0
3	BRS	L3	2063	534/10-16.ccls.	USPAT	2003/03/14 09:54			0
4	BRS	L4	4757	2 or 3	USPAT	2003/03/14 09:54			0
5	BRS	L5	85	1 and 4	USPAT	2003/03/14 09:54			0
6	BRS	L6	58	(cryptat$).ab,ti,clm.	USPAT	2003/03/14 09:54			0
7	BRS	L7	16	6 and 4	USPAT	2003/03/14 09:55			0
8	BRS	L8	3	cryptat$3 same (radiometal$ or	USPAT	2003/03/14 10:00			0

Start | Inbox - Microsoft Outlook | Document4 - Microsoft Word | United States Patent and ... | EAST - [default.wsp:1] | 10:07 AM

=> D L8
L8 HAS NO ANSWERS
L8 STR



G1 O,S,N
G2 C,N,P

Structure attributes must be viewed using STN Express query preparation.

=> D HIST

(FILE 'HOME' ENTERED AT 09:36:25 ON 14 MAR 2003)

FILE 'REGISTRY' ENTERED AT 09:36:36 ON 14 MAR 2003
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 19 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:37:48 ON 14 MAR 2003
L4 1 S L3

FILE 'REGISTRY' ENTERED AT 09:41:01 ON 14 MAR 2003
L5 STRUCTURE UPLOADED
L6 0 S L5
L7 0 S L5 FULL

FILE 'REGISTRY' ENTERED AT 09:45:07 ON 14 MAR 2003
L8 STRUCTURE UPLOADED
L9 47 S L8
L10 990 S L8 FULL

FILE 'CAPLUS' ENTERED AT 09:45:41 ON 14 MAR 2003
L11 165 S L10
L12 563285 S RADIO?
L13 36786 S RADIONUCLID? OR RADIOMETAL?
L14 2024517 S METAL?
L15 2024684 S METAL? OR RADIOMETAL?
L16 2057663 S L13 OR L15
L17 73 S L11 AND L16
L18 23042 S RADIOIMAGING OR RADIODIAGNOS? OR RADIOPHARM? OR RADIOTHER?
L19 4 S L17 AND L18

=>

=> D L1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N

G2 C,N,P

Structure attributes must be viewed using STN Express query preparation.

=> D HIST

(FILE 'HOME' ENTERED AT 09:36:25 ON 14 MAR 2003)

FILE 'REGISTRY' ENTERED AT 09:36:36 ON 14 MAR 2003
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 19 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:37:48 ON 14 MAR 2003
L4 1 S L3

=>

9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
AB Invention is directed to polychelants and their **metal** chelates which are useful in diagnostic imaging and nuclear medicine. The polychelants comprise a plurality of macrocyclic chelant moieties, e.g., DOTA residues, conjugated by thiourea, urea or glycinamide linkages to a backbone moiety through a donor atom. For example, DOTA was reacted with tetramethylguanidine and iso-Bu chloroformate to give DOTA carboxycarbonic anhydride, which upon treatment with mono-BOC-ethylenediamine yielded DOTA-N-(2-aminoethyl)amide. This was activated with thiophosgene, coupled with poly(L-lysine), and converted into a Gd complex. The Gd polychelate obtained was coupled to activated human serum albumin for use in diagnosis.
AN 2001:593292 CAPLUS
DN 135:164175
TI **Metal** polychelants for diagnostic imaging
IN Sieving, Paul F.; Watson, Alan David; Quay, Steven C.; Rocklage, Scott Michael
PA Salutar, Inc., USA
SO U.S., 13 pp., Cont.-in-part of U.S. 5,554,748.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6274713	B1	20010814	US 1995-473573	19950607
	US 5554748	A	19960910	US 1993-175989	19931230
PRAI	US 1989-335162	B2	19890407		
	US 1993-175989	A2	19931230		
	US 1990-464865	A3	19900116		

OS MARPAT 135:164175
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS
AB A new hexaazamacrobicyclic cage ligand, 1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]eicosane-1,8-diamine (SarAr) was designed for conjugation to proteins. SarAr was synthesized and characterized by microanalyses, 1H NMR and electrospray mass spectrometry. The complexation of selected transition **metal** ions (Cu(II), Ni(II) and Co(II) at 10-6 M) by SarAr was complete within 30 min over pH 6 to 8. The [64Cu(SarAr)]2+ complex was studied with a view to applications in **radioimaging**. The [64Cu(sar)]2+ complex is stable in human plasma for at least 174 h and biodistribution studies in mice, showed that the [64Cu(SarAr)]2+complex was rapidly excreted through the renal system unlike the free 64Cu2+. Overall, the simple synthesis, ready complexation behavior of SarAr, the kinetic inertness of the [Cu(SarAr)]2+ complex to dissocn. of 64Cu and its facile elimination from mice make it an attractive prospect for use in nuclear medicine.
AN 2001:541461 CAPLUS
DN 135:351935
TI Synthesis of a new cage ligand, SarAr, and its complexation with selected transition **metal** ions for potential use in **radioimaging**
AU Di Bartolo, Nadine M.; Sargeson, Alan M.; Donlevy, Therese M.; Smith, Suzanne V.
CS ANSTO, Radiopharmaceuticals R & D Division, Menai, 2234, Australia
SO Journal of the Chemical Society, Dalton Transactions (2001), (15), 2303-2309
CODEN: JCSDAA; ISSN: 1472-7773
PB Royal Society of Chemistry
DT Journal
LA English
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS
GI



I

AB The present invention relates to cryptate compds. useful as chelating agents. In particular, the present invention relates to functionalized derivs. of certain cryptate compds. These functionalized derivs. are suitable for use in radiolabeling and similar applications. The present invention also relates to a method for diagnosis or therapy of a disease using functionalized derivs. of cryptate compds. The present invention relates to a compd. which is capable of being radiolabeled (I) in which n = 2-4, where each R and R1 is independently selected from -H, CH3, COOH, NO2, CH2OH, H2PO4, HSO3, CN, C=ONH2 and CHO; X and Y are the same or different and are selected from the group of CR2, N, P and C-Z in which R2 represents a H or halogen atom or a hydroxyl, nitro, nitroso, amino, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or cyano group, or a group of the formula -COOR', COCOOR', NHCOCH2Br, -NHCOCH=CHCOOR' in which R' is a H atom or alkyl group; or; W is selected from the group of NH, S and O; and Z is a functionalized linkage group which is capable of binding said compd. (I) to a mol. recognition unit and wherein at least one of X and Y is C-Z; or a pharmaceutically acceptable salt thereof. For example 1,8-diaminosarcophagine was condensed with p-nitrobenzaldehyde to give the Schiff base which was reduced to 1-(4-aminophenylmethylamino)-8-aminosarcophagine (II) which was subsequentially complexed with 64Cu. The radiolabeling of an antibody (such as B72.3) was carried by incubating the antibody with II and complexing the immunoconjugate with 64/67Cu. The biodistribution studies with then carried out.

AN 2000:475667 CAPLUS
DN 133:114204
TI Cryptate compounds and methods for diagnosis and therapy
IN Smith, Suzanne Virginia; Harrowfield, John M.; Di Bartolo, Nadine Marie; Sargeson, Alan McLeod
PA Australian Nuclear Science & Technology Organisation, Australia; The Australian National University
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000040585	A1	20000713	WO 2000-AU3	20000105
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1147111	A1	20011024	EP 2000-902480	20000105
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	AU 1999-8038	A	19990105		
	WO 2000-AU3	W	20000105		

OS MARPAT 133:114204
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS

AB Polychelants and their **metal** chelates are provided which are useful in diagnostic imaging and in **radiotherapy** and which coprise a plurality of macrocyclic chelant moieties, e.g, DOTA residues, conjugated to a polyamine backbone mol., e.g, polylysine. To produce a site-specific polychelate, one or more of the macrocyclic chelant carrying backbone mols. may be conjugated to a site-directed macromol., e.g. a protein. Thus, DOTA was reacted with iso-Bu chloroformate, and the resulting DOTA carboxycarbonic anhydride was reacted with poly-L-lysine to give polylysine-polyDOTA. The polylysine-polyDOTA was complexed with Gd and the Gd(polylysine-polyDOTA) was coupled to human serum albumin. An MRI formulation and biodistribution data are included.

AN 1995:305593 CAPLUS

DN 122:75613

TI Polychelants containing macrocyclic chelant moieties

IN Sieving, Paul F.; Watson, Alan D.; Quay, Steven C.; Rocklage, Scott M.

PA USA

SO U.S., 16 pp. Cont.-in-part of U.S. Ser. No.335,162, abandoned.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5364613	A	19941115	US 1990-464865	19900116
	CA 2051648	AA	19901008	CA 1990-2051648	19900405
	WO 9012050	A1	19901018	WO 1990-EP565	19900405
	W: AU, CA, FI, HU, JP, NO, SU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	AU 9054235	A1	19901105	AU 1990-54235	19900405
	AU 656304	B2	19950202		
	EP 474642	A1	19920318	EP 1990-906169	19900405
	EP 474642	B1	19960626		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	EP 481526	A1	19920422	EP 1991-118887	19900405
	EP 481526	B1	19970312		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04504436	T2	19920806	JP 1990-505940	19900405
	JP 3145398	B2	20010312		
	HU 60277	A2	19920828	HU 1990-3650	19900405
	AT 139790	E	19960715	AT 1990-906169	19900405
	ES 2088428	T3	19960816	ES 1990-906169	19900405
	AT 150047	E	19970315	AT 1991-118887	19900405
	ES 2098299	T3	19970501	ES 1991-118887	19900405
	NO 9103920	A	19911127	NO 1991-3920	19911004
	NO 178866	B	19960311		
	NO 178866	C	19960619		
	US 5554748	A	19960910	US 1993-175989	19931230
PRAI	US 1989-335162	B2	19890407		
	US 1990-464865	A	19900116		
	WO 1990-EP565	A	19900405		

OS MARPAT 122:75613

=>